Radiation plus immune therapy: a new hope for tough lymphoma?
NCT ID NCT07528352
First seen Apr 25, 2026 · Last updated Apr 29, 2026 · Updated 1 time
Summary
This early-stage trial tests whether giving radiation therapy before a bispecific antibody drug (epcoritamab or glofitamab) is safe for people with a type of aggressive lymphoma (DLBCL) that has come back or not responded to at least two prior treatments. The study will enroll 12 adults and closely monitor for side effects like cytokine release syndrome and nerve-related issues. The goal is to see if this combination can be a safe option for patients with limited treatment choices.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utah, 84112, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.